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1 Introduction
We consider a randomized double-blind placebo-controlled study where the subjects are randomized
to an active treatment regime (Ri = 1) or to placebo (Ri = 0). The aim of the study is to
test whether the active treatment can reduce the risk of a failure event such as cancer or death
when compared to placebo. At enrollment a set of baseline covariates (Zi) are observed for each
subject i and in general the treatment assignment Ri can depend on Zi. The outcome of interest
(Ti) is deﬁned as the time from randomization to the event of interest, say death. The subjects
are monitored for their outcome until a pre-speciﬁed end of follow-up (Ci) and for each subject
Xi = min(Ti, Ci) and ∆i = I(Xi = Ti) are observed. During follow-up the subjects may visit a
study center at regular intervals and a number of time-dependent covariates (Li(t)) are recorded.
Treatment regime is speciﬁed in the study protocol. It may be deﬁned, for instance, to take one
capsule of the assigned treatment once a day until the end of follow-up Ci. Some subjects fail to
adhere to their intended treatment regime and stop taking the assigned capsule at some point after
enrollment. A subject’s actual receipt of active treatment is recorded by Ai(t) which equals 1 if
the subject took the active treatment at time t and 0 otherwise. We assume that subjects in the
placebo arm do not have access to the active treatment, that is in the placebo arm Ai(t) = 0 for
all i and t > 0. We call subject i in the active treatment arm a complier if Ai(t) = 1 for all t ≤ Xi
and a non-complier otherwise.
The gold standard for the analysis of a randomized study involving humans is to use the
intention-to-treat principle where the event rates in the two randomized groups are compared
regardless of subsequent adherence to the assigned treatment regime. This provides a valid test
for the null hypothesis of no treatment eﬀect because randomization implies that the two groups
are comparable on average with respect to their observed and unobserved baseline characteristics
that may inﬂuence the outcome. Thus under the null hypothesis any diﬀerences between the ob-
served event rates in the two treatment groups are due to chance via the random assignment of the
treatment. Under the alternative, the diﬀerence between the observed event rates is an unbiased
estimate of the eﬀect of the treatment assignment on the outcome. This eﬀect is generalizable to
situation where compliance and factors inﬂuencing compliance are similar as in the study settings.
The intention-to-treat estimate thus quantiﬁes the eﬀect of the treatment policy under incomplete
compliance. The intention-to-treat estimate is often referred to as the estimate of the eﬀectiveness
of the treatment policy [1]. An analysis by the intention-to-treat principle should be the primary
analysis of any randomized trial. It fulﬁls the pragmatic aim of the trial [2] of estimating the treat-
ment eﬀect when faced with incomplete compliance. The trial conditions may not be met in reality
for several reasons. For instance the knowledge of an equal chance to receive placebo may result in
poorer compliance in the trial settings, or participation in a trial may enhance compliance within
the trial. On the other hand, the published trial results may yield better compliance when the
treatment is used in general practice. Hence the estimated treatment eﬀect may not be reproduced
outside the trial settings.
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When the compliance information Ai(t) is available it is of interest to investigate the eﬀect of
the treatment actually received on the outcome. This eﬀect, which represents the biological impact
of the treatment regime, is referred to as the eﬃcacy of the treatment [1]. The explanatory aim of
the study [2] could be to quantify the magnitude of the treatment eﬀect if everyone in the study
adhered to their assigned treatment regime. This biological or causal eﬀect of the treatment is more
likely to be reproducable outside the trial settings. The treatment actually received, Ai(t), is a post-
randomization variable and may depend on the health status of the subject through measured and
unmeasured covariates. Thus the compliers and non-compliers are likely to be inherently diﬀerent
with respect to their outcome inducing non-ignorable non-compliance [3]. Therefore, an attempt
to estimate the eﬃcacy using for example a Cox model λi(t | Ai(t)) = λ0(t) exp(β × Ai(t)) with
time-dependent covariates fails because those receiving active treatment at time t are prognostically
diﬀerent from those not receiving active treatment at time t.
This thesis consist of four original research papers which are referred to as Paper I - Paper
IV. It builds on the work by Robins and co-authors [4, 5, 6, 7, 8] who use accelerated failure time
models [9] to quantify the treatment action. Each paper focusses on a particular application. In
Papers I and II we estimate the eﬀect of beta-carotene supplementation actually received and its
interactions with baseline covariates on survival in the Alpha-Tocopherol Beta-Carotene (ATBC)
Cancer Prevention Study [10, 11]. In Paper III the focus is on the estimation of the eﬀect of one dose
of vitamin A on subsequent 4 month mortality in children under 6 months of age in a randomized,
double-blind, placebo-controlled community trial in Nepal [12]. In Paper IV we estimate jointly the
eﬀects of beta-carotene supplementation, smoking cessation and their interaction on overall survival
and on time to lung cancer diagnosis in the ATBC Study. Paper IV does not directly adress the
issue of non-compliance, but smoking cessation as a post-randomization covariate, has a similar
role as compliance when its eﬀect on a survival outcome is explored. Thus similar models and
estimation principles as in Papers I-III are used in Paper IV to provide an approach for addressing
a diﬀerent subject matter question.
2 The Rubin causal model and extensions
Statistical methods that account for non-ignorable non-compliance or other post-randomization
covariates in a randomized trial build on the Rubin causal model as deﬁned by Rubin [13, 14]
and Holland [15]. As a key concept a subject may have several potential outcomes depending
on the treatment assignment and on the receipt of treatment. An outline is given below for the
statistical theory starting from binary outcomes with binary non-compliance and extending to more
complicated situations with continuous and survival outcomes and continuous non-compliance. In
all approaches the estimation relies on the distributional assumptions implied by randomization.
The more complex models need additional assumptions to make the parameters of interest estimable
from the observed data.
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2.1 Binary outcome and binary or categorical compliance
Tarwotjo et al. [16] ﬁrst considered the issue of estimating the eﬀect of treatment received in an
analysis of a randomized vitamin A trial with a control group where both the response and non-
compliance were binary. In Tarwotjo et al. [16] the response ∆i is death during a ﬁxed follow-up
period. Binary non-compliance arises from the study design in which a single oral dose of vitamin
A is randomly assigned to children in a number of randomly selected villages, while children in the
remaining villages serve as controls. A child assigned to receive the vitamin A dose either actually
reveices or does not receive it, that is either Ai = Ai(t) = 1 or Ai = Ai(t) = 0 for all t. Sommer
and Zeger [17] give a more detailed mathematical account of this approach. Randomization implies
that the expected compliance rates in the two treatment arms are the same and thus they can
construct an inferred group of compliers in the control arm who would have complied if assigned
to active treatment. Assuming that the non-compliant subgroups in the two arms have the same
expected mortality rate they derive an estimator for the eﬃcacy which avoids the inherent selection
bias that would arise if only the compliant subgroup in the treatment arm was compared with the
control arm. Cuzick el al. [18] extend the Sommer and Zeger approach to allow contamination
within the control group, that is some subjects in the control arm may receive the active treatment.
Assuming that the eﬃcacy is the same in the contaminated subgroup as in the compliant subgroup
they derive an estimator for the eﬃcacy using a standard binomial likelihood for the observed data.
They also discuss how to use their approach with censored survival data.
Goetghebeur and Molenberghs [19] extend the Sommer and Zeger approach for ordered cate-
gorical compliance. They make a monotone dose-response assumption and assume that the zero
dose outcome in the treatment group equals the outcome in the placebo group and they call this
“the placebo link assumption”. If there are more than two compliance categories the multinomial
parameters of the joint distribution of non-compliance and response are not estimable without fur-
ther restrictions on the parameters. Goetghebeur and Molenberghs use a class of models where
they restrict all global odds ratios to coincide to make the model parameters estimable.
Angrist et al. [20] use the instrumental variable approach together with potential variables
to estimate eﬃcacy. They make ﬁve explicit assumptions: (i) there is no interference between
subjects which is called the stable unit treatment value assumption in the Rubin causal model [15],
(ii) the treatment is assigned at random, (iii) the exclusion restriction holds which requires that
the treatment assignment has an eﬀect on the outcome only through its eﬀect on the treatment
received, (iv) the treatment assignment has a nonzero eﬀect on the receipt of treatment, and (v)
the monotonicity assumption holds which requires that Ai(Ri = 1) ≥ Ai(Ri = 0) where Ai(Ri = r)
denotes the treatment reveived if randomized to group r = 0 or 1. Under these assumptions Ri is
called an instrumental variable which is used to derive an estimator of the eﬃcacy parameter which
is interpreted as the average causal eﬀect of the treatment reveived in the subgroup of compliers.
Note that assumptions (i) - (v) are implicit also in the approaches above.
Imbens and Rubin [21] present Bayesian inferential methods for eﬃcacy estimands from placebo-
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controlled trials with binary non-compliance under assumptions similar to those as in Angrist et
al. [20], but with a weaker version of the exclusion restriction. They assume that the treatment
assignment is unrelated to the potential outcomes for those who would either always take or never
take the active treatment.
2.2 Continuous outcome and continuous or binary compliance
An early attempt to consider eﬃcacy in the context of randomized trials with a continuous com-
pliance measure and continuous response was presented by Efron and Feldman [22]. They focussed
on estimation of the average gain of an active treatment over placebo at a given exposure level
using a fully parametric model. They made the restricting assumption that compliance is an in-
herent attribute of the subject which is determined prior to randomization and they required that
adherence to the assigned treatment in the control arm and in the active treatment arm are similar.
Several arguments against this assumption were raised in the discussion of the paper [22]. Albert
and DeMets [23] show in simulations that even moderate deviation from the comparability of the
adherence to the assigned treatment in the two arms can introduce severe bias. The Efron and
Feldman approach further suﬀers from an unidentiﬁability problem which they can partly reduce by
deriving a lower bound for the eﬃcacy estimate at full compliance [22]. Goetghebeur and Shapiro
[24] generalize the Efron and Feldman approach by allowing the expected placebo compliance to
have shifted from the treatment compliance and they let the shift depend on measured side-eﬀects
while on active treatment and possibly also on baseline covariates. By this extra modelling assump-
tion the unidentiﬁability problem of the Efron and Feldman approach is resolved. Goetghebeur and
Lapp [25] present an application of the parametric nested mean models introduced by Robins [26]
and Robins and Greenland [27] to estimate the eﬀect of treatment at diﬀerent levels of compliance.
Based on the randomization assumption they obtain closed form estimates for the parameters of the
structural model and their covariance matrix. Very recently Frangakis and Rubin [28] addressed
the problem of estimating the eﬃcacy in the presence of binary non-compliance and subsequent
missing outcomes.
2.3 Survival outcome and continuous compliance
Robins and Tsiatis [5] ﬁrst presented a semi-parametric counter-factual approach to account for
non-compliance in randomized trials with a survival outcome. Following Rubin [14] and Holland
[15] each subject in a placebo-controlled randomized trial has at least the following four potential
survival times conceptually deﬁned prior to randomization: Ti{Ri = 1}, Ti{Ri = 0}, Ti{Ri =
1, Ai(t) = 1 for all t > 0} and Ti{Ri = 0, Ai(t) = 0 for all t > 0} where Ti{Ri = r} denotes the
survival time if subject i would be randomized to treatment arm r = 0, 1 irrespective of compliance,
Ti{Ri = 1, Ai(t) = 1 for all t > 0} denotes the survival time if subject i would be randomized to
active treatment and he would always receive active treatment and Ti{Ri = 0, Ai(t) = 0 for all t >
0} denotes the survival time if subject i would be randomized to reveice placebo and he would
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never receive active treatment. An eﬀectiveness measure of treatment assignment for subject i may
be deﬁned as the diﬀerence Ti{Ri = 1} − Ti{Ri = 0}. However, the “fundamental problem” in a
randomized trial is that for subject i we can never jointly observe all potential survival times of
interest. The “statistical solution” for the eﬀectiveness estimate is to use the average causal eﬀect of
treatment assigment E(Ti{Ri = 1})−E(Ti{Ri = 0}) where the expectation is taken over the whole
population. Randomization implies that these expectations are estimable from the two treatment
arms and thus gives the intention-to-treat estimator. When one attempts to capture the biological
eﬃcacy of active treatment one would like to compare the outcomes under ideal conditions, namely
by comparing Ti{Ri = 1, Ai(t) = 1 for all t > 0} with Ti{Ri = 0, Ai(t) = 0 for all t > 0}. Because
Ai(t) as a post-randomization covariate cannot be assigned or controlled by study design, we can
only observe one survival time Ti = Ti{Ri = ri, Ai(t) = ai} where ri is the assigned treatment
and ai is the particular realization of the actual receipt of treatment. Modelling assumptions are
needed to recover the eﬃcacy parameter from the observed data. Robins and Tsiatis [5] deﬁned
the potential outcome Ui = Ti{Ri, Ai(t) = 0 for all t > 0} as the survival time from enrollment to
the study if active treatment had been witheld throughout the study. This “treatment-free survival
time” or “placebo prognosis” is linked to the observed survival time and to the observed receipt of
treatment through a parametric accelerated failure time model
Ui
d|Zi=
∫ Ti
0
exp{ψAi(t)}ds, (1)
where the parameter ψ quantiﬁes the eﬃcacy of the treatment and
d|Zi= means equality in distribution
conditional on Zi. Model (1) describes how Ui is related to the observed Ti if subject i receives
active treatment according to the observed process Ai(t). The factor eψ can be interpreted as
the relative increase or decrease in survival if never on active treatment compared to if always on
active treatment. When the active treatment is not available outside the trial settings then we
have Ti{Ri = 0} = Ui and thus we would observe Ui in the placebo arm if there were no censoring.
In the active treatment arm we only observe Ui for uncensored subjects who do not receive active
treatment at all. In general the treatment-free survival time Ui may depend on baseline covariates
Zi and Ai(t) may depend on Ui either directly or through measured and unmeasured covariates.
Non-ignorable non-compliance in the sense of Little and Rubin [3] is thus introduced. Model (1)
can be extended to allow the treatment eﬀect to depend on baseline covariates
Ui
d|Zi=
∫ Ti
0
exp{ψ1Ai(t) + ψ2Zij ×Ai(t)}ds (2)
where ψ = (ψ1, ψ2)T quantiﬁes the treatment eﬀect for a given value of the jth baseline covariate
Zij . Randomization implies that the distribution of Ui is conditionally independent of the treatment
assigment given the baseline covariates, or equivalently
Ui ⊥⊥ Ri | Zi. (3)
This key condition is used as a basis for estimation.
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3 Estimation of the parameters of the accelerated failure
time model
3.1 The estimating procedure
We brieﬂy describe the main ideas of the estimation procedure developed in this thesis. Let us ﬁrst
assume that there is no censoring. Three assumptions are needed for estimation of ψ in models (1)
and (2): (i) the structural model (1) or (2) correctly captures the treatment action, (ii) physical
randomization takes place at baseline and the assignment mechanism is known, and (iii) Ui is
unaﬀected by the survival experiences of other individuals. The last assumption is relaxed in Paper
III where the survival times of the children within the same ward are correlated. Deﬁne a random
variable
Ui(ψ) =
∫ Ti
0
exp{ψAi(t)}ds
for model (1) and with an analogous deﬁnition of Ui(ψ) for model (2). By assumption (3) we have
at the true value ψ = ψ0
Ui(ψ0) ⊥⊥ Ri | Zi, (4)
i.e. for given Zi the treatment-free survival is independent of the treatment assignment at the
true value ψ = ψ0. Condition (4) is the key for obtaining estimating equations for ψ. Robins and
Tsiatis [5] derive an optimal and asymptotically normal estimator for ψ using a set of linear rank
test statistics. We derive an estimator for ψ by making a working assumption that the treatment-
free survival time Ui follows a proportional hazards model with respect to some baseline covariates.
Since Ui = Ui(ψ0) = Ti(Ri = 0) this assumption can be checked using data from the placebo arm.
By the working assumption we write the estimation model
λi(u) = λ0(u)ri{β(ψ), θ(ψ), Zi, Ri}, (5)
which may take the form
λi(u) = λ0(u) exp{θ1(ψ)Ri} or (6)
λi(u) = λ0(u) exp{β(ψ)Zi + θ1(ψ)Ri} or (7)
λi(u) = λ0(u) exp{β(ψ)Zi + θ1(ψ)Ri + θ2(ψ)Ri × Zi}, (8)
where λ0(u) denotes the baseline hazard of Ui(ψ), β(ψ) quantiﬁes the dependence of the risk on
the baseline covariates Zi and θ(ψ) quantiﬁes for the dependence of the risk on terms involving
Ri. Model (6) corresponds to using the log-rank test statistic as an estimating equation. By (4)
the relative risk function ri{β(ψ), θ(ψ), Zi, Ri} does not depend on terms involving Ri at the true
ψ = ψ0, or equivalently θ(ψ) = 0 at ψ = ψ0. Using the estimation model we construct a test for
the null hypothesis ψ = ψ0 ⇔ θ(ψ) = 0 using a conditional score test statistic
Q(ψ) = STθ {βˆ(ψ), θ(ψ)}Iθθ{βˆ(ψ), θ(ψ)}STθ {βˆ(ψ), θ(ψ)} (9)
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where Sθ{β(ψ), θ(ψ)} = ∂∂θ(ψ) logL{β(ψ), θ(ψ)} denotes the score function of the partial likelihood
L{β(ψ), θ(ψ)} for Ui(ψ) with Sθ{βˆ(ψ), θ(ψ)} evaluated at the value βˆ(ψ) estimated subject to the
constraint θ(ψ) = 0, I{β(ψ), θ(ψ)} = − ∂2∂β(ψ)∂θ(ψ) logL{β(ψ), θ(ψ)} and Iθθ{βˆ(ψ), θ(ψ)} denotes
the inverse of I{θ(ψ), θ(ψ)} − I{β(ψ), θ(ψ)}I−1{β(ψ), β(ψ)}I{θ(ψ), β(ψ)} evaluated at the value
βˆ(ψ) estimated subject to the constraint θ(ψ) = 0. At the true value ψ = ψ0 the score test
statistics (9) has an asymptotic χ2 distribution with p degrees of freedom, where p is the number
of parameters in ψ. A point estimate for ψ is found as the point where Q(ψ) is minimized. The
(1− α) conﬁdence set is deﬁned as the set {ψ : Q(ψ) ≤ χ2p(α)} where χ2p(α) denotes the respective
quantile of the χ2 distribution.
3.2 Censoring by end of follow-up
With censored data Ui(ψ) is not observable. Write ηi = exp(ψ) for model (1) and ηi = exp(ψ1 +
ψ2Zij) for model (2). Deﬁne
Ci(ψ) =
{
ηi Ci, if ηi < 1,
Ci, otherwise.
Further deﬁne Xi(ψ) = min{Ui(ψ), Ci(ψ)} and ∆i(ψ) = I{Ui(ψ) = Xi(ψ)}. Because both Xi(ψ)
and ∆i(ψ) are functions of baseline characteristics Ci, Zi, and since Ui(ψ) and the censoring due
to end of follow-up do not depend on Ri then at the true value ψ = ψ0
{Xi(ψ),∆i(ψ)} ⊥⊥ Ri | Zi. (10)
For given value of ψ model (5) is ﬁtted to the data {Xi(ψ),∆i(ψ)} and the score test statistic (9)
is minimized with respect to ψ by repeating the procedure for a range of values of ψ.
3.3 Censoring by competing risks
When analysing for example time to lung cancer diagnosis (T2i), some subjects die before reaching
the endpoint. Here death (T1i) is acting as a competing event and in the presence of competing
events the variables Xi(ψ) and ∆i(ψ) are not always observable. In order to adjust our estimation
method for competing events we use the approach proposed by Robins and coauthors [6, 29].
Deﬁne Xi = min(T1i, T2i, Ci). Let λT1(t | Zi, Li(t), Ri, Xi ≥ t) denote the conditional hazard
for the competing event at time t. An underlying untestable assumption needed is that at ψ =
ψ0 this hazard does not further depend on Ui(ψ) when we condition on a suﬃcient number of
baseline covariates Zi and post-randomization covariates Li(t). For this assumption to hold at
least approximately one needs to have a richly-parametrized model for λT1(t | Zi, Li(t), Ri, Xi ≥ t)
including all possible time-dependent and time-invariant covariates that might aﬀect both T1i and
Ui. The conditional probability for subject i to survive until Xi is estimated by
Kˆi = Kˆ(Xi) = exp
{
−
∫ Xi
0
λˆT1(t | Zi, Li(t), Ri, Xi ≥ t) ds
}
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using for example a Cox model with time-dependent covariates or a piecewise exponential hazard
model. In the analysis we only use data {Xi,∆i = I(Xi = T2i)} from those who do not experience
a competing event and for them Kˆ−1i is used as a weight in the estimation procedure. Heuristically
this means that a person who did not die prior to end of follow-up or prior to lung cancer diagnosis
accounts not only for himself but also for Kˆ−1i − 1 other subjects that are similar to him but died
before Xi. We need to modify the score test statistic (9) because Kˆi depends on all the data. This
is accomplished by replacing I{βˆ(ψ), θ(ψ)} by a robust covariance matrix estimator [30] in the
score test statistic (9). Robins [29] shows that this procedure leads to asymptotically conservative
conﬁdence intervals.
3.4 Modiﬁcation for missing covariates in the accelerated failure time
model
The above estimation methods are further generalized in Paper IV to the situation where some
of the covariates in the structural model may have missing values. In Paper IV time of smoking
cessation is observed only for those participants of the ATBC Study who report to have quit
smoking before withdrawal. For subjects who withdraw the smoking status is unknown. To adjust
the estimation procedure for missing information on smoking cessation we create M = 3 complete
datasets as described in section 6 of Paper IV. We combine the tests statistics (9) from each of the
m = 1, . . . ,M complete data analyses for a given value ψ using two alternative tests. For the mth
complete dataset let Sθ,m = Sθ{βˆ(ψ), θ(ψ)}, Qm = Q(ψ) and Iθθm = Iθθ{βˆ(ψ), θ(ψ)}. The ﬁrst test
statistic by Li et al. [31] is deﬁned as
D(ψ) =
S¯Tθ U¯
−1S¯θ
p(1 + r)
where S¯θ = M−1
∑
Sθ,m, U¯ = M−1
∑
(Iθθm )
−1, r = p−1(1 + M−1)tr(BU¯−1) and B = (M −
1)−1
∑
(Sθ,m − S¯θ)(Sθ,m − S¯θ)T with summation over m. Under the null the test statistic D(ψ)
has an F reference distribution with p and ν1 = 4 + [p(M − 1) − 4][1 + r−1(1 − 2p(M−1) )]2 degrees
of freedom [31]. Another test statistic proposed by Rubin [32] combines directly the test statistics
(9) and is deﬁned as
ˆˆ
D(ψ) =
p−1Q¯− M−1M+1 rˆ
1 + rˆ
where Q¯ =M−1
∑
Qm, rˆ =
(1+M−1)s2
2Q¯+max(0,4Q¯2−2ps2) and s
2 = (1−M)−1∑(Qm − Q¯)2. Under the null
ˆˆ
D(ψ) has an F reference distribution with p and ν2 = 2−1(1 + p−1)(M − 1)(1 + rˆ−1)2 degrees of
freedom. A point estimate for ψ is found as the value which minimizes D(ψ) or ˆˆD(ψ) and the joint
(1 − α) conﬁdence region is deﬁned as the set {ψ : D(ψ) ≤ Fp,ν1(α)} or {ψ : ˆˆD(ψ) ≤ Fp,ν2(α)}
where Fp,ν1(α) and Fp,ν2(α) denote the (1 − α) percentage points of the respective F reference
distributions.
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3.5 Previous applications of the accelerated failure time models
There exist several applications of the accelerated failure time models in the context of randomized
and observational studies. Robins et al. [6] estimate the eﬀect of a post-randomization prophylaxis
treatment on the survival of AIDS patients in an observational study. There is no physical ran-
domization in an observational study and for estimation purposes one needs to model explicitly the
evolution of the treatment received over time. Robins et al. [6] model the hazard of initiation of
the prophylaxis treatment at time t using a richly-parametrized time-dependent Cox model which
conditions on a large number of time-dependent and time-invariant covariates. Assuming that the
Cox model is correctly speciﬁed the inferences rely on the assumption that the hazard does not
futher depend on the treatment-free survival time. This assumption is referred to as “the assump-
tion of no unmeasured confounders”. Further applications of accelerated failure time models in an
observational setting can be found in Mark and Robins [33], Joﬀe et al. [34], Keiding et al. [35]
and Witteman et al. [36].
The ﬁrst use of accelerated failure time models in the context of a randomized clinical trial with
non-compliance was by Mark and Robins [37], who estimated the eﬀect of smoking cessation on
overall survival in the Multiple Risk Factor Intervention Trial. Robins and Greenland [27] ﬁrst used
a two-parameter accelerated failure time model when estimating the direct eﬀect of AZT treatment
and the eﬀect of a post-randomized prophylaxis treatment on survival in a randomized study with
AIDS patients. They used two linear rank tests, the log-rank test and the Prentice-Wilcoxon test, to
obtain the estimating equations for the two parameters of the accelerated failure time model. White
and Goetghebeur [38] also used a two-parameter accelerated failure time model when studying the
eﬀect of an anti-hypertensive treatment on survival. They used the model, however as a tool for a
sensitivity analysis when examining how post-randomized treatment changes aﬀected the intention-
to-treat estimates. White et al. [39] used a two-parameter model with the same estimating equations
as in Robins and Greenland [27].
4 Summaries of the original papers
Each paper of this thesis focusses on a particular application aimed at answering speciﬁc subject
matter research questions. The papers and the datasets of each application are summarized below.
4.1 Paper I. Correcting for non-compliance in randomized trials: An
application to the ATBC Study
The application of Paper I arises from the ATBC Study [10]. Brieﬂy, the ATBC Study was a
randomized, double-blinded, placebo-controlled chemoprevention trial conducted in 14 adjoining
areas of Finland between 1985 and 1993. The objectives of the study were to evaluate the eﬀects
of alpha-tocopherol and beta-carotene supplementations on lung cancer incidence, on incidence of
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other major cancers and on total mortality in a cohort of 29133 middle aged male smokers being at
high risk for lung cancer. The participants were recruited between 1985 and 1988. The scheduled
end of the active intervention was April 30, 1993. Within each area a 2 × 2 factorial scheme was
used to randomize the participants to one of the four possible treatments, alpha-tocopherol alone,
beta-carotene alone, combination of them, or placebo. At the time of randomization the censoring
time Ci was ﬁxed and known for each participant and deﬁned as the diﬀerence between April
30, 1993 and the date of randomization. Paper I considers only two randomized groups, namely
the group of 14560 men who were assigned to receive beta-carotene (BC group) and 14573 men
assigned not to receive beta-carotene (NOBC group). Note that the BC group includes combination
treatment as well as beta-carotene treatment alone. Similarly, the NOBC group includes placebo
treatment and alpha-tocopherol treatment alone. At baseline the participants were interviewed and
details of their demographic variables, their medical, smoking, dietary and occupational history were
recorded. Levels of alpha-tocopherol and beta-carotene in serum were also measured from blood
samples drawn at baseline. During follow-up three annual visits to the local ﬁeld center were made,
during which the men were asked about their health status and smoking habits since the last visit.
At the follow-up visits unused study capsules from the previous period were returned, counted and
recorded, and a new pack with a 4-month supply was given to each participant. If the participants
stopped attending follow-up visits they could no longer get the study supplementation and were
considered as withdrawals. Endpoint information was received from national registers regardless
of the withdrawal status of the participants. Speciﬁcally, deaths were conﬁrmed via the Central
Population Register and lung cancers were identiﬁed through the Finnish Cancer Registry and
further reviewed by the Clinical Review Commitee for conﬁrmation and staging.
The intention-to-treat analyses suggested a harmful eﬀect of beta-carotene on both lung cancer
incidence and total mortality. The relative risk estimate was 1.08 (95 % CI from 1.01 to 1.16) for
total mortality [11]. This is an estimate of the eﬀectiveness. However 25 % of the men withdrew
from the BC group for reasons other than death and time after withdrawal in the BC group
accounted for about 15.1 % of the total follow-up time in that arm (Table IV of Paper I). Thus
non-compliance caused by withdrawal from the BC arm is quite substantial and the estimate of
eﬀectiveness is attenuated compared to an estimate of eﬃcacy. It is thus of interest to estimate the
eﬀect of beta-carotene supplementation actually received on overall survival.
Paper I compares three diﬀerent approaches for the analysis: the intention-to-treat (ITT) ap-
proach based on a Cox proportional hazards model with the treatment assignment Ri as a covariate,
the as-treated (AT) approach based a Cox proportional hazards model with the treatment received
Ai(t) as a time-dependent covariate and the g-estimation (GE) approach using a one-parameter
accelerated failure time model with a log-rank test statistic as an estimating equation. The GE
approach amounts to using the estimation method of section 3.1 with (6) as the estimation model.
A simulation study performed under diﬀerent non-compliance settings indeed showed that the ITT
estimate is attenuated towards null due to non-compliance (Table III and Figures 1 and 2 of Paper
I). It was further shown that the AT approach gives valid estimates only if (i) Ui follows an expo-
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nential distribution and (ii) non-compliance is independent of Ui. The GE approach performs well
in all non-compliance settings.
The analysis of the ATBC Study suggests that non-compliance is related to the treatment-free
survival time through measured baseline covariates and possibly also through other unmeasured
covariates, which induces non-ignorable non-compliance (Table V of Paper I). Thus the AT approach
is inappropriate. Based on the GE approach the survival time is estimated to be 7.4 % shorter if
one would always be on beta-carotene supplementation as opposed to never being on beta-carotene
supplementation (Table VI of Paper I). Comparing this with the accelerated failure time ITT
estimate of 5.4 % reduction demonstrates the attenuation.
4.2 Paper II. Eﬀect modiﬁcation in a randomized trial under nonignorable
noncompliance: An application to the ATBC Study
The estimation method described in section 3.1 is developed in Paper II. The estimation model (7)
which conditions on one baseline covariate is compared in simulations with Robin’s g-estimation
approach that uses (6) as the estimation model. Simulations show a substantial increase in precision
with the former method (Table 1 of Paper II) and also that the method performs well under the null
even if the estimation model miss-speciﬁed (Table 3 of Paper II). Paper II also provides simulation
based techniques for evaluating the adequacy of the accelerated failure time model. The simulations
suggest that when the correct model is (2) and the analysis is done without the interaction term
using model (1) the method may detect such a model miss-speciﬁcation (Figure 1 of Paper II). Miss-
speciﬁcation of the functional form of the covariate in the model (2) was, however, not detected.
The aim of the application of Paper II is to estimate the eﬀect of beta-carotene actually received
on total mortality in the ATBC Study and to quantify how eﬀect modiﬁcation by baseline covariates
such as age, smoking, alcohol consumption and serum beta-carotene level. This paper is the ﬁrst to
address the estimation of an interaction in a real application. The analysis of Paper II is restricted
to those 27025 men who did not have missing values on covariates of interest (Table 4 of Paper II).
It was found that none of the studied interactions was statistically signiﬁcant but all of them had
the same signs as in the stratiﬁed analysis (Figure 3 and Table 5 of Paper II). It was estimated
that for a person who smokes 10 cigarettes per day more than on average the lifespan would be
12.2 % shorter if one would always reveive beta-carotene supplementation than if one would never
reveive beta-carotene supplementation. Similarly for a person with the daily alcohol comsumption
10 g/day more than on average the survival time would be 8.7 % shorter if always on beta-carotene
supplementation than if never on beta-carotene supplementation. With increasing levels for the
baseline serum beta-carotene level the harmful eﬀect of beta-carotene supplementation decreased.
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4.3 Paper III. Vitamin A and infant mortality: Beyond intention-to-
treat in a randomized trial
In Paper III we investigate the eﬀect of one oral dose of vitamin A on subsequent 4 month mortality
in children under 6 months of age in a randomized, double-blind, placebo-controlled community trial
in Nepal with partially unobserved non-compliance. Between September 1989 and December 1991,
261 wards in 29 contiguous village development areas in the rural plains of Nepal were randomly
allocated either to receive an oral dose of vitamin A or placebo every 4 months [12]. Households
in the wards were visited every 4 months with a maximum of 6 visits. Starting from the second
visit, infants born since the previous visit were enrolled and dosed. In total 9178 newborns entered
the study over the 5 visits of interest. At enrollment social economic information like the caste
to which the children belong and the number of radios owned by their household were recorded.
Arm circumference was measured at each visit and morbidity in the week preceding dosing was
reported in terms of number of days the child had had diarrhea, fever and cough. We censored
follow-up time at 4 months after the ﬁrst dose was scheduled and before a second dose was possibly
given. There is no loss-to-followup, and hence the censoring time is known at entry for each child.
All children did not receive their vitamin A or placebo capsule: approximately 85 % were dosed
immediately by the ﬁeld staﬀ and about 2 % did never receive their intended dose. For about 13
% of the children capsules were left at home with their parents and we do not know whether the
capsule was taken or not. For these 13 % the precise compliance status is thus unknown. Table 1
of Paper III shows the number of children entering the study at visits 2 to 6 and in parentheses the
number of those who died within 4 months stratiﬁed by treatment group and compliance category.
Within the deﬁned follow-up time, 173 of the 9178 children died (1.9 %), 77 in the placebo group
and 96 in the vitamin A group.
The data of the trial oﬀer two new challenges for the accelerated failure time model approach:
(i) ward-based randomization induces correlation between survival outcomes within the same ward
and (ii) the actual receipt of vitamin A dose is not always known. For (i) we use a robust version
of the estimation method of Paper II that replaces I{βˆ(ψ), θ(ψ)} by a robust covariance matrix
estimator in the score test statistic (9). For (ii) we use two diﬀerent deﬁnitions for compliance we
perform a sensitivity analysis which captures the boundaries for the estimated parameters. In the
analysis it was found that the eﬀect of vitamin A was beneﬁcial in the beginning of the trial but
towards the end of the trial there was a reversal of this eﬀect (Tables 4 and 6 of Paper III).
4.4 Paper IV. Joint estimation of eﬀects of beta-carotene supplementa-
tion and smoking cessation on overall survival and on time to lung
cancer diagnosis in the ATBC Study
In Paper IV we estimate the eﬀects of beta-carotene supplementation, smoking cessation and their
interaction on overall survival and on time to lung cancer diagnosis in the ATBC Study. About
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21 % of the men in the ATBC Study stopped smoking during the active follow-up period and a
naive analysis of the data suggested that the harmful eﬀect of beta-carotene supplementation on
total mortality and on lung cancer incidence was more pronounced among quitters (Tables 1 and
2 of Paper IV). The naive analysis is subject to selection bias and should not be interpreted as
evidence for an interaction. In order to evaluate the possible interaction we use accelerated failure
time models where time to smoking cessation has a similar role as non-compliance because it is a
post-randomization covariate. An additional challenge for the analysis arises because the smoking
status after dropout is unknown for those men who were smokers at the time of dropout (Table 3 of
Paper IV). Based on the work of Paper II we propose an extention to the inference prodecure that
accounts for the unknown smoking status using a multiple imputation scheme. This was described
in section 3.4. In the analysis of time to lung cancer diagnosis we adjust for censoring due to
competing risk by death as described in section 3.3.
In the analysis of total mortality in the ATBC Study data we compared the performance of
the two test statistics D(ψ) and ˆˆD(ψ) which gave practically the same answers (Figure 1 of Paper
IV). Because ˆˆD(ψ) requires less space for storage it was used in subsequent analyses. We found
no evidence of an eﬀect of smoking cessation or an interaction on either overall survival or on time
to lung cancer diagnosis. A sensitivity analysis showed the eﬀect of beta-carotene supplementation
was harmful for both endpoints for a range of values for the eﬀect of smoking cessation (Figures
3 and 4 of Paper IV). Under the assumption of no eﬀect of smoking cessation the survival time
was estimated to be 4.9 % (0.5 % to 9.1 %) shorter in the beta-carotene supplementation arm than
in the arm with no beta-carotene supplementation (Table 4 of Paper IV). Similarly, the eﬀect of
beta-carotene supplementation was estimated to shorten the time to lung cancer diagnosis by 10.4
% (3.4 % to 16.9 %) (Table 5 of Paper IV).
5 Concluding remarks
Compliance issues have recently gained much attention in the medical statistics literature. An ex-
ample of the increasing interest among researchers is the one-day compliance symposium arranged
at Limburg University in 1995 which was publised in Statistics in Medicine [40]. While the analy-
sis by intention-to-treat remains the gold standard for comparing diﬀerent treatment strategies in
a clinical trial setting, information on post-randomization covariates such as compliance can give
useful knowledge about the eﬃcacy of the treatment. The estimation of the eﬃcacy is not possible
without additional non-identiﬁable assumptions. The perhaps strongest assumption made through-
out this thesis is that the treatment eﬀect can be captured by the accelerated failure time model. In
Papers I and II we provide some graphical and simulation-based techniques for evaluating whether
an interaction term should be included in the accelerated failure time model, but otherwise we need
to rely on the correctness of the speciﬁed accelerated failure time model. With competing risks
a further assumption of “no unmeasured confounders” is introduced, which cannot be empirically
tested. As pointed out by Dunn [41] an underlying assumption that should be recognized is that
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compliance is assumed to be error-free. It is plausible that the actual receipt of treatment is mea-
sured with error especially in the case where compliance is assessed through capsule count as in the
ATBC Study. This will cause the estimates to be biased and modiﬁcation of the accelerated failure
time modelling approach to allow for measurement error is thus motivated.
In Paper II we develop an estimation method which can easily be used with a multi-parameter
structural accelerated failure time model. The eﬃciency of the proposed estimation procedure was
demonstrated in simulations in Paper II. The power of the estimation method is still rather poor.
Robins and Tsiatis [5] describe a class of estimators which includes an optimal estimator whose
asymptotic variance attains a semi-parametric eﬃciency bound. They discuss an adaptive procedure
to ﬁnd an estimator whose asymptotic eﬃciency may be close to that of the optimal estimator. The
practical impementation of this procedure would, however, be tedious and the magnitude of the
gain in eﬃciency is likely to be of little practical consequence. Another way of increasing eﬃciency
is to turn the randomized trial into an observational study where one explicitly models the active
treatment process after randomization. Under the assumption of “no unmeasured confounders”
one can obtain estimating equations for the treatment eﬀect parameter. One practical example of
this is the observational analysis by Mark and Robins [33], which shows a signiﬁcant improvement
in eﬃciency over the previous analysis which used a log-rank test statistic for estimation [37]. The
drawback of this approach is, however, that the assumption of “no unmeasured confounders” cannot
be empirically tested and thus may result in biased estimation.
Loeys and Goetghebeur [42] suggested a modiﬁcation to our estimation procedure by estimating
β(ψ) from the estimation model (5) using data only from the placebo arm. They obtained a closed
form estimator for the structural parameter in the binary compliance case by assuming exponentially
distributed treatment-free survival time. However, in the more complex situation of continuous
compliance the structural parameter estimator does not exist in closed form.
The analyses from the ATBC Study in Paper I and II suggest that the eﬀect of beta-carotene
supplementation is more harmful when the analyses are adjusted for non-compliance. This is a
consequence of models (1) and (2) which assume a constant acceleration rate over time. The
accelerated failure time model can be modiﬁed to accomodate diﬀerent dose-response mechanisms,
for instance by using the cumulative dose process
∫ t
0
Ai(u)du instead of Ai(t). The models (1)
and (2) also assume that after withdrawal there is no treatment eﬀect. Again, a more ﬂexible
model that allows the treatment to have an eﬀect on survival also after withdrawal could be used.
While the power of the proposed estimation methods remains to be improved this thesis provides
estimation tools that easily extend to more complex models of treatment action when addressing
the eﬀect treatment received on a survival outcome in a randomized placebo-controlled study with
non-ignorable non-compliance.
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